NICE-Style Value-Based Pricing Might Actually Boost Antibiotic Sales In U.S.
Executive Summary
Antibiotic development could expand if the U.S. adopted a system to evaluate the drugs’ effectiveness and value to society for reimbursement purposes, similar to that of the British National Institute for Health and Clinical Excellence, according to an article in the Sept. 7 issue of the journal Health Affairs.
You may also be interested in...
Antibiotics Need REMS For Public, Not Patient, Safety Reasons, IDSA Says
Overuse of antibiotics could be controlled using elements of FDA’s Risk Evaluation and Mitigation Strategies, the Infectious Diseases Society of America argues in an upcoming position paper.
Antibiotics Need REMS For Public, Not Patient, Safety Reasons, IDSA Says
Overuse of antibiotics could be controlled using elements of FDA’s Risk Evaluation and Mitigation Strategies, the Infectious Diseases Society of America argues in an upcoming position paper.
Restanza Superiority Trials Intended To Avoid Non-Inferiority "Quagmire"
Advanced Life Sciences CEO Michael Flavin decided a pair of superiority trials was the best way to prove the efficacy of the company’s Restanza in community-acquired bacterial pneumonia, given the "stalemate" at FDA regarding the use of non-inferiority trials in antibiotics.